NICE has defended a trio of decisions on new therapies for multiple myeloma, which saw two drugs approved for restricted use in England and Wales and a third turned down altogether.
There will soon be two gene therapies available for patients with haemophilia B in the EU after the European Commission approved Pfizer's fidanacogene elaparvovec under the Durveqtix brand
MSD has reported phase 2b/3 data with its clesrovimab antibody for respiratory syncytial virus (RSV) preventions in infants, which could be a challenger to Sanofi and AstraZeneca's fast-gro
Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category – but has now decided on a lead candidate.
Pfizer’s chief scientific officer and president of R&D, Mikael Dolsten, has said he will step down from the role in the coming months, kicking off the search for a successor.